Tag Archives: YTD

IndexIQ Announces March 2013 Performance of Its IQ Hedge Family of Investable Benchmark Hedge Fund R

By Business Wirevia The Motley Fool

Filed under:

IndexIQ Announces March 2013 Performance of Its IQ Hedge Family of Investable Benchmark Hedge Fund Replication Indexes

RYE BROOK, N.Y.–(BUSINESS WIRE)– IndexIQ, a leading developer of index-based alternative investment solutions, today announced the performance of its proprietary family of hedge fund replication and alternative beta indexes.

Designed as investable benchmarks that replicate the performance characteristics of sophisticated hedge fund strategies, the IQ Hedge™ benchmark indexes were originally introduced on March 30, 2007, and have been calculating live since that date. IQ Hedge is the first family of investable benchmark indexes covering hedge fund replication/alternative beta strategies.

For the period ended March 31, 2013, the returns for the indexes were as follows:

…read more
Source: FULL ARTICLE at DailyFinance

 
IQ HEDGE FUND REPLICATION – Beta Indexes
    1 Month   3 Month   YTD

Why You Should Completely Ignore Daily Stock Prices

By David Hanson, The Motley Fool

Filed under:

The American spirit fosters competition. We constantly measure ourselves against our peers and gloat about our accomplishments. Every day, investors point to their stock positions that jumped into the green and feel a sense of accomplishment.

In the investing community, the presence of daily stock prices has resulted in investors either feeling warm and fuzzy because their holding increased during the trading day or sick and nauseous if their daily position ticked into the red. When even great ones like Warren Buffett scoff at the idea of constantly checking daily quotes, why do investors continuously feel the urge to pull up their brokerage account or flip on CNBC? The answer can be chalked up to human nature and a lack of patience.

One of the most heavily traded stocks is Bank of America . Almost every investor has an opinion about the future prospects of the megabank, and the company’s stock price is constantly thrust onto front pages. After hordes of retail investors swore off the bank and vowed to never get burned again, the stock went on to more than double in 2012. An annual return of +100% is not something every investor experiences. By looking beyond the absolute annual return and into the daily movements, an interesting pattern emerges.

If one was to check Bank of America’s share price every single trading day of 2012 and not look at the YTD returns, I doubt many, if any, would predict gains of over 100%. The following graph is the breakdown of B of A’s stock performance each day of 2012:

Source: Google Finance.

The fact that Bank of America shares doubled in a year and still traded lower for almost half of the daily trading sessions highlights the lack of importance of obsessively tracking one’s daily positions. More so, not all of the daily declines were insignificant as Bank of America shares declined more than 1% during almost 28% of the trading days in 2012.

Stocks, particularly bank stocks, will undoubtedly jump up and down as external events impact the broader market, earnings miss forecasts, and fear or greed enters the marketplace. If investors continually focus on the market‘s short-term reactions to macro events or brief doubts about a company, countless opportunities will surely be missed. I am not advocating ignorance in regards to managing a portfolio, but if one is too shortsighted to recognize the lack of importance of daily movements, perhaps that person is better off handing his or her money to someone who can.

Forget that Bank of America’s stock doubled in 2012. Is there more yet to come? With significant challenges still ahead, it’s critical to have a solid understanding of this megabank before adding it to your portfolio. In The Motley Fool’s premium research report on B of A, analysts Anand Chokkavelu, CFA, and Matt Koppenheffer, Financials bureau chief, lift the veil on the bank’s operations, including detailing three reasons to buy and three reasons …read more
Source: FULL ARTICLE at DailyFinance

Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013

By Business Wirevia The Motley Fool

Filed under:

Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013

SAN DIEGO–(BUSINESS WIRE)– Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NAS: GALE) , NewLink Genetics Corporation (NAS: NLNK) , Vical Incorporated (NAS: VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.

Year-to-date, the now fifteen Cancer Index members have posted an average 32% gain (161% Annualized). This is more than double the 15% average YTD appreciation of the NASDAQ, S&P, and NYSE Biotech Indices.

The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first ten weeks of 2013 follow: Galena Biopharma Corporation +39.87%, NewLink Genetics Corporation +0.08%, Vical Incorporated +43.30%, Inovio Pharmaceuticals, Inc. +7.65%, Dendreon (NAS: DNDN) +10.40%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +40.10%, Agenus (NAS: AGEN) +6.59%, Oncothyreon (NAS: ONTY) +15.63%, Biovest International (Pink Sheets:BVTIQ) -56.00%, Celldex Therapeutics (NAS: CLDX) +78.24%, Northwest Biotherapeutics (NAS: NWBO) +17.96%, CEL – SCI Corp. (NYSE MKT:CVM) -4.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +40.18% and Advaxis, Inc. (OTCBB:ADXS) +199.67% – all for an average 2013 YTD gain of +31.85%. (Annualized rate: 161.48%).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Mentor Capital, Inc.
Chester Billingsley, CEO
(760) 788-4700

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Mentor Capital Cancer …read more
Source: FULL ARTICLE at DailyFinance

Commodity Prices Fall in February Despite Positive Economic News

By Business Wirevia The Motley Fool

Filed under:

Commodity Prices Fall in February Despite Positive Economic News

The UBS Bloomberg CM Commodity Index (CMCITR) continues to outperform other “constant maturity” indexes year-to-date

NEW YORK–(BUSINESS WIRE)– The UBS Bloomberg Constant Maturity (“CM”) Commodity Total Return Index (ticker: CMCITR), a modern commodity index designed to reduce the potential negative effects of contango, returned -4.02 percent in February, following an increase of 2.62 percent in January, according to data released today by Van Eck Global and Bloomberg. The index has returned -1.51 year-to-date.

Commodity indexes declined in February as several positive news developments failed to boost commodity demand growth. The U.S. economy continued to strengthen as housing starts moved to their highest levels since 2009, while U.S. retail sales increased and better-than-expected U.S. jobless claims data hinted at a sustained recovery in U.S. employment. There were also signs that the Chinese economy is improving, as exports in China continued to rise and imports moved to their highest level since February 2012. However, commodities appeared to face strong headwinds from the pending U.S. government “sequester” and the release of the Federal Reserve‘s most recent meeting minutes, which indicated a potential end to its quantitative easing program.

While all commodities sectors turned negative in February, energy was the least negative performing sector of the month, as a decline in natural gas inventories offered some relief to a lack of oil demand growth. Agriculture weakened on increased supply, while livestock and industrial metals fell. The precious metals sector was the worst performer for the month, falling to seven-month lows following the release of the aforementioned Fed minutes.

CMCITR roll yield was positive for the period. WTI contango widened as Brent backwardation narrowed. Natural gas contango widened and remained within manageable levels. Wheat contango narrowed and sugar moved back into contango during the month. Copper, gold and silver contango all narrowed in February.

CMCITR outperformed the other main “constant maturity” indexes during the month, including the Continuous Commodity Index (CCITR: -4.31 percent, -2.19 percent YTD) and the Greenhaven Continuous Commodity Index (GCC: -4.38 percent, -2.24 percent YTD).

During February, CMCITR also outperformed the more traditional Dow Jones UBS Commodity Index (DJUBSTR), which returned -4.09 percent (-1.79 percent YTD) and the S&P Goldman Sachs Commodity Index (SPGSCITR), which returned -4.38 percent (-0.22 percent YTD).

CMCITR diversifies across 28 commodity components and up to five maturities. The Index was designed to minimize investment exposure …read more
Source: FULL ARTICLE at DailyFinance

Value Is Back! Should You Bet on It?

By Alex Dumortier, CFA, The Motley Fool

Filed under:

With stocks opening higher this morning, the Dow Jones Industrial Average
is now looking for its 10th consecutive winning day. Meanwhile, the broader S&P 500
would be happy to beat its all-time high of 1,565.15, set in October 2007. This has proven an elusive milestone so far — surely it cannot be much longer now? The Dow and the S&P 500 are up 0.34% and 0.27%, respectively, as of 10:15 a.m EDT.

The style cycle has turned
According to fund-tracking company Lipper, the best-performing funds in 2012 were in the “value” category, which is now beating its “growth” counterpart for the first time in five years. Did value managers suddenly become more astute than their growth-oriented brethren? The answer is no, as the following annual-performance data for growth- and value-style indexes demonstrates (winning return in bold):

 Fiscal Year

Russell 1000 Growth

Russell 1000 Value

2013 (YTD as of March 13)

8.2%

11.4%

2012

15.3%

17.5%

2011

2.6%

0.4%

2010

16.7%

15.5%

2009

37.2%

19.7%

2008

(38.4%)

(36.8%)

Source: Russell Indexes. YTD = year to date.

The Russell 1000 Value beat the Russell 1000 Growth in 2012 for the first time since 2008. Keep in mind that the Russell style indexes are unmanaged vehicles: They are constructed according to an algorithm that ranks stocks according to factors including book-to-price ratio, forecast earnings growth, etc. My point is that if value managers are now beating growth managers, it is mainly a product of the style cycle.

It’s interesting to note that the last year in which value outperformed was during a brutal bear-market drubbing, whereas value’s current outperformance is occurring in (or, perhaps, despite) a bull market. Are investors acting more defensively than the headlines heralding all-time market highs suggest? In fairness, one of the reasons growth has been underperforming comes down to a single stockApple, the largest component in growth indexes. Apple shares are off nearly 40% from last year’s all-time high.

What are the implications for investors? If you’re mainly an asset-allocation investor, you’ll already be tracking the style cycle closely. If you’re a stock picker, it need not affect your stock selection, but it’s worth knowing which headwinds or tailwinds your portfolio faces as you seek to realize its full value. Right now, it looks like value stocks have the wind in their sails.

If you’re looking for long-term investing ideas that will generate returns independent of the style cycle, check out the Fool’s special report: “The 3 Dow Stocks Dividend Investors Need.” It’s absolutely free, so just click here and get your copy today.

The article Value Is Back! Should You Bet on It? originally appeared on Fool.com.

Fool contributor Alex Dumortier, CFA has no position in any stocks mentioned; you can follow him on <a target=_blank …read more
Source: FULL ARTICLE at DailyFinance